{"id":55555,"date":"2021-08-06T12:02:30","date_gmt":"2021-08-06T12:02:30","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=77261"},"modified":"2021-08-06T12:02:30","modified_gmt":"2021-08-06T12:02:30","slug":"gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/","title":{"rendered":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results"},"content":{"rendered":"<div>\n<div id=\"m_divBody\">\n<div id=\"m_divWide\">\n<p>BEVERLY HILLS, Calif., Aug. 6, 2021 \/PRNewswire\/ &#8212; GT Biopharma, Inc. (&#8220;GT Biopharma&#8221; or the &#8220;Company&#8221;) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company&#8217;s proprietary natural killer (NK) cell engager (TriKE\u2122) protein biologic technology platform, today announced that the management team will host a conference call to discuss second quarter 2021 financial results and general business updates on August 13, 2021 at 8:30 a.m. EST.<\/p>\n<div id=\"m_dvprnejpg68ableft\" dir=\"ltr\"><img decoding=\"async\" id=\"m_prnejpg68ableft\" class=\"alignright\" title=\"GT Biopharma Logo\" src=\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\" alt=\"GT Biopharma Logo\" width=\"248\" height=\"150\" align=\"middle\" border=\"0\" \/><\/div>\n<p>To join the call:<\/p>\n<ul type=\"disc\">\n<li>U.S. callers should dial 1-877-870-4263 and international callers should dial 1-412-317-0790.<\/li>\n<li>All participants should ask to be connected to the GT Biopharma conference call.<\/li>\n<\/ul>\n<p>The call will be available by visiting the &#8220;Presentations&#8221; page in the &#8220;News &amp; Media&#8221; section of GT Biopharma&#8217;s website at <a href=\"https:\/\/www.google.com\/url?q=https:\/\/c212.net\/c\/link\/?t%3D0%26l%3Den%26o%3D3251717-1%26h%3D4047053914%26u%3Dhttps%253A%252F%252Fwww.gtbiopharma.com%252Fnews-media%252Fpresentations%26a%3Dwww.gtbiopharma.com%252Fnews-media%252Fpresentations&amp;source=gmail-html&amp;ust=1628337685100000&amp;usg=AFQjCNHs444UiISSTnBIhB-qVSGy_BQ2Nw\"  rel=\"noreferrer\">www.gtbiopharma.com\/news-<wbr \/>media\/presentations<\/a>. A replay of the call will be archived for 30 days following the presentation.<\/p>\n<p><b>About GT Biopharma, Inc.<\/b><\/p>\n<p>GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE\u2122 NK cell engager platform. Our TriKE\u2122 platform is designed to harness and enhance the cancer killing abilities of a patient&#8217;s immune system&#8217;s natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE\u2122 technology. For more information, please visit <a href=\"https:\/\/www.google.com\/url?q=https:\/\/c212.net\/c\/link\/?t%3D0%26l%3Den%26o%3D3251717-1%26h%3D127055007%26u%3Dhttps%253A%252F%252Fwww.gtbiopharma.com%252F%26a%3Dgtbiopharma.com&amp;source=gmail-html&amp;ust=1628337685100000&amp;usg=AFQjCNFqfE2NrHIESEkgxpqc9pYAjpV0RA\"  rel=\"noreferrer\">gtbiopharma.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials.\u00a0Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as &#8220;believes&#8221;, &#8220;hopes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;projects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221; and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.\u00a0Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended\u00a0December\u00a031, 2020, in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A, filed with the\u00a0Securities and Exchange Commission\u00a0(the &#8220;SEC&#8221;) on\u00a0April 16, 2021\u00a0any of which could cause actual results to differ materially from those indicated by our forward-looking statements.<\/p>\n<p>Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things:\u00a0(i)\u00a0the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii)\u00a0our ability to complete our contemplated clinical trials, or to meet the\u00a0FDA&#8217;s\u00a0requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv)\u00a0our ability to achieve approval of a marketable product, (v)\u00a0design, implementation and conduct of clinical trials, (vii)\u00a0the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii)\u00a0the market for, and marketability of, any product that is approved, (viii)\u00a0the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix)\u00a0regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x)\u00a0various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.<\/p>\n<p>We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section\u00a027A of the Securities Act, to the extent applicable.\u00a0Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.<\/p>\n<p><b>Contact:<\/b><\/p>\n<p><i>Institutional Investors:<br \/>\n<\/i>Brendan Payne<br \/>\nStern Investor Relations, Inc.<br \/>\n<a href=\"mailto:brendan.payne@sternir.com\"  rel=\"noreferrer\">brendan.payne@sternir.com<\/a><br \/>\n212-362-1200<\/p>\n<p>Investor &amp; Media Relations:<br \/>\nDavid Castaneda<br \/>\n<a href=\"mailto:David@gtbiopharma.com\"  rel=\"noreferrer\">David@gtbiopharma.com<\/a><br \/>\n414-351-9758<\/p>\n<p>Logo &#8211; <a href=\"https:\/\/www.google.com\/url?q=https:\/\/c212.net\/c\/link\/?t%3D0%26l%3Den%26o%3D3251717-1%26h%3D3946317542%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1483265%252FGTBP_SmallLogo_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1483265%252FGTBP_SmallLogo_Logo.jpg&amp;source=gmail-html&amp;ust=1628337685100000&amp;usg=AFQjCNHN2iPCxA2j6jkLJzg3YzFGGmVLtA\"  rel=\"noreferrer\">https:\/\/mma.prnewswire.com\/<wbr \/>media\/1483265\/GTBP_SmallLogo_<wbr \/>Logo.jpg<\/a><\/p>\n<\/div>\n<div id=\"m_divMediaContact\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEVERLY HILLS, Calif., Aug. 6, 2021 \/PRNewswire\/ \u2014 GT Biopharma, Inc. (\u201cGT Biopharma\u201d or the \u201cCompany\u201d) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company\u2019s proprietary natural killer (NK) cell engager (TriKE\u2122) protein biologic technology platform, today announced that the management team will host a conference call to [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,343],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette\" \/>\n<meta property=\"og:description\" content=\"BEVERLY HILLS, Calif., Aug. 6, 2021 \/PRNewswire\/ \u2014 GT Biopharma, Inc. (\u201cGT Biopharma\u201d or the \u201cCompany\u201d) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company\u2019s proprietary natural killer (NK) cell engager (TriKE\u2122) protein biologic technology platform, today announced that the management team will host a conference call to [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Lebanon News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-06T12:02:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"lnadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"lnadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\"},\"author\":{\"name\":\"lnadmin\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\"},\"headline\":\"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results\",\"datePublished\":\"2021-08-06T12:02:30+00:00\",\"dateModified\":\"2021-08-06T12:02:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\",\"articleSection\":[\"MENA\",\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\",\"name\":\"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\",\"datePublished\":\"2021-08-06T12:02:30+00:00\",\"dateModified\":\"2021-08-06T12:02:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage\",\"url\":\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\",\"contentUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lebanonnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"name\":\"Lebanon News Gazette\",\"description\":\"News from Lebanon\",\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\",\"name\":\"Lebanon News Gazette\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"contentUrl\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"width\":503,\"height\":261,\"caption\":\"Lebanon News Gazette\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\",\"name\":\"lnadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"lnadmin\"},\"url\":\"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/","og_locale":"en_US","og_type":"article","og_title":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette","og_description":"BEVERLY HILLS, Calif., Aug. 6, 2021 \/PRNewswire\/ \u2014 GT Biopharma, Inc. (\u201cGT Biopharma\u201d or the \u201cCompany\u201d) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company\u2019s proprietary natural killer (NK) cell engager (TriKE\u2122) protein biologic technology platform, today announced that the management team will host a conference call to [\u2026]","og_url":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/","og_site_name":"Lebanon News Gazette","article_published_time":"2021-08-06T12:02:30+00:00","og_image":[{"url":"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg"}],"author":"lnadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"lnadmin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#article","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/"},"author":{"name":"lnadmin","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840"},"headline":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results","datePublished":"2021-08-06T12:02:30+00:00","dateModified":"2021-08-06T12:02:30+00:00","mainEntityOfPage":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/"},"wordCount":793,"publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage"},"thumbnailUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg","articleSection":["MENA","Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/","url":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/","name":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results - Lebanon News Gazette","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage"},"thumbnailUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg","datePublished":"2021-08-06T12:02:30+00:00","dateModified":"2021-08-06T12:02:30+00:00","breadcrumb":{"@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#primaryimage","url":"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg","contentUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/pak7lSr2lMmwgGMnAh9fvZGuTo_wi85MClwiXebIpzE-gE1Ru8TbkzbWX-MatxxLGojFGNNmpuUB25at53grpvrNT6MmXGo6Jxy2f6zFNythYI4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1483265\/GTBP_SmallLogo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/lebanonnewsgazette.com\/gt-biopharma-to-host-conference-call-to-discuss-second-quarter-2021-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lebanonnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results"}]},{"@type":"WebSite","@id":"https:\/\/lebanonnewsgazette.com\/#website","url":"https:\/\/lebanonnewsgazette.com\/","name":"Lebanon News Gazette","description":"News from Lebanon","publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lebanonnewsgazette.com\/#organization","name":"Lebanon News Gazette","url":"https:\/\/lebanonnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","contentUrl":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","width":503,"height":261,"caption":"Lebanon News Gazette"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840","name":"lnadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"lnadmin"},"url":"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/55555"}],"collection":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/comments?post=55555"}],"version-history":[{"count":0,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/55555\/revisions"}],"wp:attachment":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/media?parent=55555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/categories?post=55555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/tags?post=55555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}